ADMA Biologics (NASDAQ:ADMA) Hits New 1-Year High – Time to Buy?

ADMA Biologics, Inc. (NASDAQ:ADMA) reached a new 52-week high during trading on Friday . The company traded as high as $22.30 and last traded at $21.67, with a volume of 779556 shares traded. The stock had previously closed at $19.72.

Wall Street Analysts Forecast Growth

ADMA has been the subject of a number of recent research reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. HC Wainwright reaffirmed a “buy” rating and set a $18.00 target price on shares of ADMA Biologics in a report on Monday, October 14th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $15.50.

ADMA Biologics Stock Up 13.5 %

The company has a quick ratio of 2.80, a current ratio of 6.87 and a debt-to-equity ratio of 0.74. The firm has a market capitalization of $5.22 billion, a PE ratio of 154.79 and a beta of 0.64. The business’s 50-day moving average price is $18.01 and its 200-day moving average price is $13.73.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.08 by $0.05. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm had revenue of $107.20 million for the quarter, compared to the consensus estimate of $86.44 million. During the same quarter in the previous year, the company posted ($0.02) earnings per share. The business’s quarterly revenue was up 78.4% compared to the same quarter last year. As a group, equities research analysts predict that ADMA Biologics, Inc. will post 0.49 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, CEO Adam S. Grossman sold 236,889 shares of the business’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other ADMA Biologics news, Director Jerrold B. Grossman sold 136,861 shares of the firm’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the sale, the director now directly owns 467,305 shares in the company, valued at $8,070,357.35. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Assenagon Asset Management S.A. raised its stake in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock valued at $69,454,000 after buying an additional 92,281 shares in the last quarter. LSV Asset Management bought a new position in ADMA Biologics during the first quarter worth about $1,028,000. Seven Eight Capital LP acquired a new stake in ADMA Biologics during the second quarter valued at approximately $1,992,000. Louisiana State Employees Retirement System bought a new stake in shares of ADMA Biologics in the 3rd quarter valued at approximately $2,253,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of ADMA Biologics by 152.2% in the 1st quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock worth $4,837,000 after buying an additional 442,315 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors and hedge funds.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.